Audited Integrated Financials for quarter and year ended 31.03.2025
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.9 pts less than Nifty Microcap 250 and 7.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Albert David Limited reported a sharp decline in full-year FY25 profitability. Revenue from operations fell to Rs. 34,576.80 Lacs from Rs. 36,246.17 Lacs (down ~4.6%), while total income dropped to Rs. 37,534.87 Lacs from Rs. 42,001.38 Lacs due to a steep fall in other income. Profit After Tax collapsed to Rs. 1,720.08 Lacs from Rs. 7,542.01 Lacs (down ~77%), with EPS falling to Rs. 30.14 from Rs. 132.15. The Q4 quarter alone posted a loss of Rs. 1,032.79 Lacs versus a profit of Rs. 1,291.26 Lacs in Q4 FY24. Operating cash flow swung to negative Rs. 2,843.58 Lacs versus positive Rs. 4,550.22 Lacs last year, mainly due to a sharp Rs. 2,028.99 Lacs inventory build-up. The Board has recommended a final dividend of Rs. 5 per share (50%), and reappointed internal, secretarial, and cost auditors for FY26. Statutory auditor M/s. L. B. Jha & Co. issued an unmodified (clean) audit opinion.
Despite a clean audit report and steady dividend, shareholders face a significant earnings decline with profits down over three-quarters and a quarterly loss in Q4. Weak operating cash flow and rising costs may weigh on short-term sentiment, though the stock remains a low-debt, dividend-paying pharmaceutical company.